Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adrenal hyperplasia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44300   clinical trials with a EudraCT protocol, of which   7354   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Adrenal hyperplasia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-004764-22 Sponsor Protocol Number: SPR001-203 Start Date*: 2020-10-15
    Sponsor Name:Spruce Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004381-19 Sponsor Protocol Number: NBI-74788-CAH2006 Start Date*: 2021-06-07
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by O...
    Medical condition: Classic Congenital Adrenal Hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Ongoing) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004878-34 Sponsor Protocol Number: ATR-101-202 Start Date*: 2018-09-18
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005822-23 Sponsor Protocol Number: REK231814 Start Date*: 2012-10-16
    Sponsor Name:Haukeland University Hospital
    Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA
    Medical condition: Congenital adrenal hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Ongoing) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004873-17 Sponsor Protocol Number: NBI-74788-CAH3003 Start Date*: 2020-10-15
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-...
    Medical condition: Classic Congenital Adrenal Hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002395-40 Sponsor Protocol Number: AGO/2013/007 Start Date*: 2014-03-24
    Sponsor Name:Ghent University Hospital
    Full Title: Prospective intervention trial with adjuvant metformin in girls and boys with classic CAH (METFOR CAH).
    Medical condition: congenital adrenal hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004765-40 Sponsor Protocol Number: SPR001-204 Start Date*: 2020-11-17
    Sponsor Name:Spruce Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Co...
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned) EE (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000711-40 Sponsor Protocol Number: DIUR-005 Start Date*: 2015-11-19
    Sponsor Name:Diurnal Ltd
    Full Title: A Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia.
    Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-005448-32 Sponsor Protocol Number: DIUR-006 Start Date*: 2016-07-20
    Sponsor Name:Diurnal Ltd
    Full Title: A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia (CAH)
    Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000051-10 Sponsor Protocol Number: A091200 Start Date*: 2008-05-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: 11C metomidate PET scanning for Conn's syndrome
    Medical condition: Primary hyperaldosteronism - Conn's syndrome and bilateral adrenal hyperplasia. Imaging of adrenal lesions using 11C-metomidate PET. Pre-suppression with dexamethasone and/or fludrocortisone to opt...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003996-32 Sponsor Protocol Number: 69HCL14-0447 Start Date*: 2015-11-03
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Multicentric evaluation of in utero dexamethasone (DEX) on the cognitive development of children at risk of Congenital Adrenal Hyperplasia - PRENATAL DEX Study
    Medical condition: Patient with Congenital Adrenal Hyperplasia (CAH) or sibling of a CAH patient . Patient no connection with Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10061630 Adrenogenital syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000458-40 Sponsor Protocol Number: Infacort004 Start Date*: 2015-10-20
    Sponsor Name:Diurnal Limited
    Full Title: Open-label, long-term follow-up of safety and biochemical disease control of Infacort® in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enr...
    Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. ...
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001069-20 Sponsor Protocol Number: HIDROGUM21 Start Date*: 2022-01-12
    Sponsor Name:Vall d'Hebron Hospital Universitari
    Full Title: Tolerability and acceptance of two oral hydrocortisone compounding formulation for pediatrics
    Medical condition: Adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004802-24 Sponsor Protocol Number: NL68556.091.18 Start Date*: 2019-05-20
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia
    Medical condition: Congenital adrenal hyperplasia (CAH) is a disorder of adrenal steroid synthesis leading to cortisol deficiency and an increase in androgen production.Treatment in children consists of hydrocortis...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004956-12 Sponsor Protocol Number: CORT125134-456 Start Date*: 2021-02-24
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-...
    Medical condition: Hypercortisolism
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004860 10020611 Hypercortisolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) BG (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004467-26 Sponsor Protocol Number: DIUR-015 Start Date*: 2022-02-08
    Sponsor Name:Diurnal Limited
    Full Title: A Phase 3 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia
    Medical condition: Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002265-30 Sponsor Protocol Number: Infacort003 Start Date*: 2015-02-19
    Sponsor Name:Diurnal Limited
    Full Title: A Phase 3 open-label study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency.
    Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. Cu...
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000748-32 Sponsor Protocol Number: SPI-62-CL-2002 Start Date*: 2023-08-29
    Sponsor Name:Sparrow Pharmaceuticals, Inc.
    Full Title: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
    Medical condition: Hypercortisolism Related to a Benign Adrenal Tumor
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004860 10020611 Hypercortisolism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001104-37 Sponsor Protocol Number: ME/2011/3709 Start Date*: 2014-10-06
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia
    Medical condition: Addison's disease and Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10011195 Cortisol LLT
    17.0 100000004848 10020518 Hydrocortisone LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-003668-29 Sponsor Protocol Number: DIUR-014 Start Date*: 2022-02-04
    Sponsor Name:Diurnal Limited
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study of Chronocort Compared with Immediate-Release Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over with Congenital ...
    Medical condition: Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA